Iron chelation therapy in MDS: what have we learnt recently?

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic blood transfusions in myelodysplastic syndromes (MDS) can lead to iron overload.
• Iron overload negatively impacts organ function and survival in MDS patients.
• Iron chelation therapy is recommended for managing iron overload in MDS.

Purpose of the Study:

• To review guidelines on managing iron overload in MDS.
• To evaluate the role and benefits of iron chelation therapy in MDS patients.
• To highlight the specific benefits of deferasirox in MDS.

Main Methods:

• Analysis of published guidelines on MDS management.
• Review of evidence on iron chelation therapy efficacy and safety.
• Examination of deferasirox's mechanism of action in MDS.

Main Results:

• Guidelines generally agree that lower-risk MDS patients benefit most from iron chelation.
• Deferasirox effectively reduces serum ferritin and labile plasma iron.
• Deferasirox exhibits an acceptable safety profile and may inhibit the NF-kappaB pathway.

Conclusions:

• Iron chelation therapy is crucial for managing iron overload in MDS patients.
• Deferasirox is an effective oral chelator with potential additional benefits in MDS.
• Targeting iron overload and related pathways may improve MDS patient outcomes.